- Akebia (NASDAQ:AKBA) is scheduled to announce Q2 earnings results on Friday, August 25th, before market open.
- The consensus EPS Estimate is -$0.03 and the consensus Revenue Estimate is $59.1M (-53.4% Y/Y).
- Over the last 1 year, AKBA has beaten EPS estimates 75% of the time and has beaten revenue estimates 75% of the time.
- Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 2 upward revisions and 0 downward.
- Recent earnings Analysis from our contributors:Akebia Therapeutics: Take Profits Before Second Quarter Report
More on Akebia
- Akebia: 'Hold' Through Regulatory And Financial Hurdles
- Akebia Therapeutics: Take Profits Before Second Quarter Report
- Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue
- Akebia plans to resubmit vadadustat NDA by end of Q3
- Akebia to resubmit FDA application for kidney drug by end of Q3
- Akebia settles last patent lawsuit related to kidney disease therapy
- Akebia jumps 16% as Piper upgrades after updates on kidney disease candidate
- Seeking Alpha’s Quant Rating on Akebia
- Earnings data for Akebia